Deals in Depth: October 2009
Executive Summary
Sanofi-Aventis was the standout in pharma alliances, penning three of the big deals, which together were worth over $1 billion in potential deal value. Onyx's buy of cancer and immunology biotech Proteolix topped the M&A chart at $851 million. In devices, notable was Kimberly-Clark, which followed up last month's Baylis acquisition with another in pain management--I-Flow, for $309 million, over twice that company's sales. Almost 40% of pharma financing came from Talecris' $600 million notes offering. And fundraising for the device industry was boosted by an $88 million IPO completed by AGA Medical Holdings, and a $55 million Series B from TransEnterix.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.